References
- Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
- Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed?. A population-based prevalence study. BJU Int 2001;87:760-6
- Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
- Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-15
- Wyman JF, Burgio KL, Newman DK. Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence. Int J Clin Pract 2009;63:1177-91
- Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 2009;19:380-94
- Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
- Toviaz (fesoterodine fumarate). Full Prescribing Information. New York, NY: Pfizer Inc November 2008
- Toviaz (fesoterodine fumarate). Summary of the Product Characteristics. New York, NY: Pfizer Inc, 2007
- Malhotra BK, Crownover PH, Labadie R, et al. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. Eur J Clin Pharmacol 2010;66:171-76
- Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008;9:1787-96
- Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998;63:529-39
- Nilvebrant L, Hallen B, Larsson G. Tolterodine – a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997;60:1129-36
- Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther 2008;46:556-63
- Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
- Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
- Dmochowski RR, Peters KM, Morrow JD, et al. Randomized, double-blind, placebo-controlled study of flexible-dose fesoterodine in subjects with overactive bladder. Urology 2010;75:62-68
- Abrams P, Kelleher C, Lerr L, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:S580-90
- Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care 2009;15:S98-107
- Dmochowski R, Kreder K, MacDiarmid S, et al. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. BJU Int 2007;100:107-10
- Khullar V, Rovner ES, Dmochowski R, et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008;71:839-43